Human Insulin
Human Insulin is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Novolin R, Novolin N, Novolin 70/30. Available dosage forms: injection, solution, injection, suspension.
Drug details
- Generic Name
- Human Insulin
- Brand Names
- Novolin R, Novolin N, Novolin 70/30
- Application Number
- BLA019938
- Sponsor
- Novo Nordisk
- NDC Codes
- 12
- Dosage Forms
- INJECTION, SOLUTION, INJECTION, SUSPENSION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- INSULIN HUMAN
Indications and Usage
1 INDICATIONS AND USAGE NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )